2.15 USD
▼-0.13-5.70%
盘后 1.94 0.00%
2026-11-20
市值
$97.24M
市盈率
—
EPS
-0.88
股息率
—
52 周区间
1.77 – 5.89
成交量
266.79K
Beta
0.66
目标价
18.83
52W 低 1.7752W 高 5.89
价格走势
公司简介
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product...